The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
Open accessAbstract
Insulin-dependent diabetes may occur in patients with cancers who are treated with checkpoint inhibitors (CPIs). We reviewed cases occurring over a 6-year period at two academic institutions and identified 27 patients in whom this developed, or an incidence of 0.9%. The patients had a variety of solid-organ cancers, but all had received either anti–PD-1 or anti–PD-L1 antibodies. Diabetes presented with ketoacidosis in 59%, and 42% had evidence of pancreatitis in the peridiagnosis period. Forty percent had at least one positive autoantibody and 21% had two or more. There was a predominance of HLA-DR4, which was present in 76% of patients. Other immune adverse events were seen in 70%, and endocrine adverse events in 44%. We conclude that autoimmune, insulin-dependent diabetes occurs in close to 1% of patients treated with anti–PD-1 or –PD-L1 CPIs. This syndrome has similarities and differences compared with classic type 1 diabetes. The dominance of HLA-DR4 suggests an opportunity to identify those at highest risk of these complications and to discover insights into the mechanisms of this adverse event.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“To date, the majority of immune checkpoint inhibitor -related cases of type 1 diabetes occur in people with high-risk HLA-DR4 (present in 76% of individuals), whereas other high-risk HLA alleles are not more common than those in the general population (67).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [67]
The cited source says what the claim attributes to it.
In the citing paper
“This immune-related adverse event occurs in just under 1% of checkpoint inhibitor -treated individuals but most commonly occurs with agents that block the programmed cell death protein 1/programmed cell death ligand 1 pathway alone or in combination with other checkpoint inhibitors (67).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [67]
The cited source says what the claim attributes to it.
In the citing paper
“This immune-related adverse event occurs in just under 1% of checkpoint inhibitortreated individuals but most commonly occurs with agents that block the programmed cell death protein 1/programmed cell death ligand 1 pathway alone or in combination with other checkpoint inhibitors (66).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [66]
The cited source says what the claim attributes to it.
In the citing paper
“A new and emerging issue is the development of profound insulin deficiency associated with the use of immune check-point inhibitors, which may present with hyperglycemia and diabetic ketoacidosis (DKA) (4).”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It is still unclear if steroid-sparing regimens decrease the risk of PTDM with studies showing mixed results.1591–1595”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1593]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationTivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Self-citationLymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. N. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,455
Overcoming T cell exhaustion in infection and cancer
Pauken, K. E., & Wherry, E. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.008 · Cited by 1,220
Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3064 · Cited by 1,115
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J., Salama, A. D., Chitnis, T., Smith, R. N., Yagita∥, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 817
Research works printed but not linked: 1
- Alzenaidi, 2017, Autoimmune diabetes presented with diabetic ketoacidosis induced by immunotherapy in an adult with melanoma, J La State Med Soc, 169, 49
Cited by
Sorted by citations
Items 501–594 of 594
The PD-1 Checkpoint Receptor Maintains Tolerance of Self-Reactive CD8 T Cell in SkinPreprint
Damo, M., Cui, C., William, I., Hornick, N. I., Kwok, D. W., Clulo, K., Damsky, W., Leventhal, J. S., & Joshi, N. S. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3883633 · Cited by 1
Expert system verification and validation for nuclear power industry applications
Naser, J. A. (1990) · Transactions of the American Nuclear Society · Cited by 1
Editorial: Decoding checkpoint inhibitor-induced endocrinopathies
Burnett, D. L., Barnet, M. B., & Samaras, K. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.987648 · Cited by 1
Tsang, V., McGrath, R. T., Clifton-Bligh, R. J., Scolyer, R. A., Jakrot, V., Guminski, A. D., Long, G. V., & Menzies, A. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa144
Kotwal, A., & Kudva, Y. C. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa143
Gómez, P. R. D. V., Romero, M. D. C. T., Morales, C., Olmedo, I. S., & Brocca, M. A. M. (2020) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2020.07.005
Shore, N. D. (2020) · Bladder Cancer · doi:10.3233/blc-200362
Optimizing Care for Patients With Adverse Events From Immunotherapeutics
Sheehan, K., Price, C. C., & Hafez, N. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000492
Immunopathogenesis of Immune-Related Adverse Events from Cancer Immunotherapy
Calabrese, L. H. (2021) · Springer eBooks · doi:10.1007/978-3-030-56824-5_3
Kitayama, S., Nakata, N., & Iwata, M. (2021) · Research Square · doi:10.21203/rs.3.rs-517777/v1
Endocrinopathies Associated With Immune Checkpoint Inhibitors
Girotra, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-76097-3.00024-7
The immunoregulation of autoimmune diabetes
Hu, H. (2021) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/3sz5-xf29
Gestion des toxicités de l’immunothérapie
Ricordel, C., Guen, Y. L., & Léna, H. (2021) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(21)00118-x
Endocrinology aspects of other clinical or physiological situations
Brooke, A. M., Hirwa, K., Higham, C., & Lewis, A. A. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198851899.003.0012
Interferon/interleukin-2/monoclonal antibodies
(2018) · Reactions Weekly · doi:10.1007/s40278-018-51237-2
Clinical Features of Camrelizumab-Associated Diabetes Mellitus
Ye, D., Qiu, M., Wu, L., & Li, B. (2022) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001493
Diabetes mellitus de comienzo abrupto secundaria a pembrolizumab
Alcaraz, A. P., Marín-Martínez, L., Kyriakos, G., Martín, M. C. Á., & Alonso, E. H. (2022) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2022.06.005
Case 13: Rapid-Onset Type 1 Diabetes and Ketoacidosis
Rimmalapudi, D., & Ipp, E. (2021) · American Diabetes Association eBooks · doi:10.2337/9781580407663.13
Case 19: Immune Checkpoint Inhibitor–Induced Type 1 Diabetes
Aktürk, H. K., & Michels, A. W. (2021) · American Diabetes Association eBooks · doi:10.2337/9781580407663.19
Immunotherapy and Endocrine Oncology
Contreras, M., Sánchez, J. C., & Iglesias, P. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_242-1
Tian, Y., Li, T., Ding, H., Zhao, X., Luo, J., Chen, K., Tang, Z., Huang, L., Li, L., & Yang, L. (2022) · Journal of Clinical Case Studies · doi:10.16966/2471-4925.258
Research progress on mechanisms and predictive biomarkers for immune-related adverse eventsPreprint
Zhang, Y., Qu, Z., Zhang, T., Zhao, Z., Zhang, Y., & Gu, K. (2023) · Research Square · doi:10.21203/rs.3.rs-2494743/v1
Dermatologic autoimmunity associated with immune checkpoint inhibitors
Elshot, Y. S., Blok, S. G., Bekkenk, M. W., & Matos, T. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85389-7.00015-6
Endocrine Consequences Following Immune Checkpoint Inhibitors Therapy
Lavrentaki, A., & Ntali, G. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_172-1
徐, 慧. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.133469
Wu, L., Tsang, V., Menzies, A. M., Sasson, S. C., Carlino, M. S., Brown, D. A., Clifton-Bligh, R. J., & Gunton, J. E. (2023) · doi:10.2337/figshare.22373224
Wu, L., Tsang, V., Menzies, A. M., Sasson, S. C., Carlino, M. S., Brown, D. A., Clifton-Bligh, R. J., & Gunton, J. E. (2023) · doi:10.2337/figshare.22373224.v1
A review on mesenchymal stem cell-based therapies for autoimmune disorders
Sinha, Y., Nair, G. J., Srivastava, A. K., Kumar, N. S., & Hiremath, L. (2023) · World Journal of Biology Pharmacy and Health Sciences · doi:10.30574/wjbphs.2023.15.2.0363
Rivera, A. L., Carulla, D., Capó, A., & Rodríguez, M. (2023) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v57i2.628
Secondary diabetes mellitus: focusing on type 3c diabetes and post-immunotherapy new onset diabetes
Ragni, A. (2023) · The Journal of AMD · doi:10.36171/jamd23.26.2.8
Nikolaos, N., Christantoniou, G., Kyrka, K., Pezirkianidou, P., Bikos, V., Papadaki, K., & Tsiouda, T. (2023) · Journal of Pulmonology and Respiratory Research · doi:10.29328/journal.jprr.1001047
[Advances in Predictive Research of Immune Checkpoint Inhibitors-related Adverse Events].
Zhang, J., Chen, X., & Ma, S. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.106.20
Bah, M., Bouché, C., & Gautier, J. (2023) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2023.1312017
Cancer immunotherapy-associated endocrine complications and treatment strategies
Sen, K., Adhikari, M., Biswas, C., Maity, S., Chatterjee, A., & Pramanick, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95114-2.00010-8
Immunogenicity of Stem Cell Derived Beta Cells
den Hollander, N. H. M., & Roep, B. O. (2023) · Springer eBooks · doi:10.1007/978-3-031-41943-0_13
Wechselwirkung zwischen eingeschränkter Insulinsekretionskapazität und Insulinresistenz
Würfel, M., Tönjes, A., & Stümvoll, M. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01148-2
Klein, C. R., & Feldmann, G. (2024) · Angewandte Nuklearmedizin · doi:10.1055/a-2182-6499
TAKIZAWA, H., & Ogawa, O. (2024) · Cureus · doi:10.7759/cureus.55616
Cancer in diabetes: Who is who?
García‐Jiménez, C., García-Martínez, J. M., & Chocarro‐Calvo, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00003-8
Yang, X., Wang, Z., Niu, J., Zhai, R., Xue, X., Wu, G. G., Fang, Y., Meng, G., Yuan, H., Zhao, L., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22619005
Nivolumab-Induced Diabetic Ketoacidosis: A Case Report
Giese, D., Elkhedr, A. E., Jnaneswaran, G., & Ernste, K. M. (2024) · Cureus · doi:10.7759/cureus.64319
Wagner, C. A., Smith, K., James, J. A., & James, E. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00025-4
Endocrine toxicity of cancer immunotherapy
Das, N., Tarenia, S. S., & Kalra, S. (2024) · International Journal of Molecular and Immuno Oncology · doi:10.25259/ijmio_19_2024
Immuncheckpoint-Inhibition – Basiswissen für die klinische Praxis
Klein, C. R., & Feldmann, G. (2024) · Radiopraxis · doi:10.1055/a-2340-0416
Çağlayan, M., & Eren, O. Ö. (2023) · doi:10.69860/nobel.9786053359111.43
Etiopatogenia y situación epidemiológica de la diabetes mellitus tipo 1
Cebada, A. B., Silva, J. B. Q., Escobar-Morreale, H. F., & Chávez, L. N. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.10.001
Diaphragmatic Palsy Due to a Paraneoplastic Autoimmune Syndrome Revealed by Checkpoint Inhibitors
Destival, J.-B., Michot, J., Cauquil, C. A., Noël, N., Hacein‐Bey‐Abina, S., Chrétien, P., & Lambotte, O. (2024) · Reports — Medical Cases Images and Videos · doi:10.3390/reports7040084
Izumi, K., Iyoda, T., Yokota, A., Kanno, M., Hoshi, M., Tokuda, E., Sasaki, E., Kanazawa, K., Kuroda, J., & Saji, S. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08928-y
Tak, M. B., Munir, Z., & Aydın, A. (2024) · Cureus · doi:10.7759/cureus.73049
Direct or Indirect Endocrine and Metabolic Consequences of Malignancies
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-5759-4
Immunotherapy for Endocrine Oncology
Contreras, M., Sánchez, J. C., & Iglesias, P. (2024) · Springer eBooks · doi:10.1007/978-3-030-80962-1_242-2
Blanco-Carrasco, A. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-69895-8_51
Rizvi, S. S., Gianarakis, M., Pueringer, J., Méndez, G., Garrad, E. C., Chuy, V., Chandran, S., Holscher, C., & Ali, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24742-2.00018-6
Ruiz-Esteves, K. N., Deutsch, A. J., & Rengarajan, M. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2024.6476
Colombo, C., Leo, S. D., Campisi, I., Palesandro, E., Turco, F., Buttigliero, C., Fugazzola, L., & Tucci, M. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104627 · Cited by 1
Diabètes fulminants spontanés et induits
Chaillous, L., & Smati, S. (2025) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2025.04.014
Worsening Hyperglycemia During Immune Checkpoint Inhibitor Therapy
Lee, I. J.-A., Takigawa, K., & Best, C. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-83533-9_8
Diabetes und onkologische Immuntherapien: Schwerer Autoimmundiabetes durch Immuntherapien möglich
Brandenburg, T., Klose, J. M., Feldkamp, J., & Tan, S. (2025) · Deutsches Ärzteblatt · doi:10.3238/persdia.2025.06.27.01
ONKOLOGINIŲ LIGŲ IMUNOTERAPIJOS SUKELIAMOS ENDOKRINOPATIJOS
Gendvilas, V. (2025) · Health Sciences · doi:10.35988/sm-hs.2025.137
Crowder, V., & Brady, V. (2025) · Life · doi:10.3390/life15071063
李, 镜. (2025) · Asian Case Reports in Emergency Medicine · doi:10.12677/acrem.2025.133037
Tomiki, M., Matoba, K., Sekiguchi, K., Jinnai, S., & Nishimura, R. (2025) · Internal Medicine · doi:10.2169/internalmedicine.5970-25
Immunotherapy for Endocrine Oncology
Contreras, M., Sánchez, J. C., & Iglesias, P. (2025) · Springer eBooks · doi:10.1007/978-3-032-00769-8_242
Endocrine Consequences Following Immune Checkpoint Inhibitors Therapy
Lavrentaki, A., & Ntali, G. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_172
Du, J., Manna, A. K., Medina-Serpas, M. A., Hughes, E. P., Bisoma, P., Evason, K. J., Young, A., Wilson, W. D., Brusko, T. M., Farahat, A. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.22.683978
Self-citationIyer, P. C., Kikani, N. J., Khan, S., Chaudhri, A., Pagnotti, G. M., Best, C. J., Weitzman, S., Mehta, P. P., Lavis, V. R., Thosani, S., et al. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2593621
Fernandez, J., Feun, L. G., Torres, J. V., & Nguyen, D. M. (2025) · EMJ Oncology · doi:10.33590/emjoncol/qjsi5311
Lyadova, M. A., Анатольевна, П. О., Fedorinov, D. S., Antonova, T. G., Khachaturian, E., & Sobolev, M. M. (2025) · Journal of Modern Oncology · doi:10.26442/18151434.2025.3.203304
Wei, H.-H., Lai, Y.-C., Lin, G., Lin, C.-W., Chang, Y.-C., Chang, J. W., Liou, M.-J., & Chen, I.-W. (2024) · Figshare · doi:10.6084/m9.figshare.25045585
Hyperglycémies iatrogènes en dehors du virus de l’immunodéficience humaine
Treca, P., & Amouyal, C. (2025) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(24)46693-6
Predicting checkpoint inhibitor-associated autoimmune diabetes: prospects and limitations
Herold, K. C., & Perdigoto, A. L. (2026) · Journal of Clinical Investigation · doi:10.1172/jci202477
Self-citationTuháčková, M., & Brož, J. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.090
非小細胞肺がんにおける免疫チェックポイント阻害薬の免疫関連有害事象に関する研究
藤本, 愛. (n.d.) · Institutional Repositories DataBase (IRDB)
PD-1/PD-L1 pathway and the U-Curve paradigm: implications for type 1 diabetes immunotherapy
Chen, J., Zhang, H., Yu, P., Fu, L., & Yang, P. (2026) · European journal of medical research · doi:10.1186/s40001-026-04455-0
Andrade, L. J. D. O., de Oliveira, G. C. M., de Melo, P. R. S., & de Oliveira, L. M. (2026) · Research Square · doi:10.21203/rs.3.rs-9595012/v1
Uncommon or Rare Forms of Diabetes: From Diagnosis to Management
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-7878-0
Nishikido, S., Mishima, H., Yoshiura, K., Sakamoto, N., Ishimoto, H., Morimoto, S., Horie, I., Akazawa, S., Haraguchi, A., Tsujiguchi, H., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1840622
Wang, R. (2026) · Theoretical and Natural Science · doi:10.54254/2753-8818/2026.34578
Chen, L. R., Cooksley, T., Kochhar, R. S., Raj, E. J. T., Lorigan, P. C., & Adam, S. (2026) · Diabetes Care · doi:10.2337/dc26-0700
Alharbi, T. H., Alzahrani, H. A., Alromaihi, R. A., alzahrani, S., Alromaihi, M., & Kamrul-Hasan, A. B. M. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113439
The metabolic roles of immune checkpoint molecules
Wang, Y., Wang, J., Dan, S., Zheng, J., Lu, Y., & Xia, F. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag030
Athanasiadou, K. I., Pavlou, P., Qureshi, A., Brackenridge, A., & Liu, Y. (2026) · Diabetic Medicine · doi:10.1111/dme.70439
Hyperglycemia during ICI Therapy: etiology, risk factors, and survival outcome
Shen, M., Wang, X., Gao, T., Yin, J., Bian, W., Zheng, X., Yang, T., & Shi, Y. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03018-8
Matteoli, C., Mazzone, A., & Verna, R. (2026) · Annals of Laboratory Medicine · doi:10.3343/alm.2025.0733
Ashfaq, F., Alawadi, F., Bashier, A. M., & Ahamed, F. (2026) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0046-1825859
McGillivray, E., Kane, S., Saadatkhah, A., & Yeung, K. T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1950429
Liu, Y., Xu, T., Chen, Z., Zhang, W., Wang, T., Yan, W., Xie, Y., Li, H., & Cai, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1935980
Almeida, J. B., & Weiss, G. J. (2026) · Journal of Patient Safety · doi:10.1097/pts.0000000000001585
Pembrolizumab-induced fulminant type 1 diabetes mellitus: a case report and literature review
Sun, S., Su, L., Ma, X., & 窦建新 (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1958726
Yan, Y., Yue, W., 宋华, 李子榕, Li, W., Liu, X., Pan, J., & Cai, S. (2026) · Research Square · doi:10.21203/rs.3.rs-11026242/v1
Amer, B., Alnukhali, M., Haidarah, A., & Ahmad, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1845336
Type 1 diabetes mellitus during immune checkpoint inhibitor therapy in cancer patients
Орлова, Р. В., Gerk, I., Itkin, I. M., Cheverda, O. V., Avramenko, A., Belyak, N. P., & Zhukova, N. V. (2026) · Clinical Case in Oncology · doi:10.62546/3034-1477-2026-4-1-7-19
Polyfunctional T Helper Cells in Checkpoint-Induced Diabetes
Lechner, M. (2026) · ImmPort · doi:10.21430/m35w7q4efr
Metadata
- Authors
- Stamatouli, A. M., Quandt, Z., Perdigoto, A. L., Clark, P. L., Kluger, H., Weiss, S. A., Gettinger, S., Sznol, M., Young, A., Rushakoff, R., Lee, J., Bluestone, J. A., Anderson, M., & Herold, K. C.
- Affiliations
- Yale University (US)
- University of California, San Francisco (US)
- Corresponding author
- Herold, Kevan C.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2018-06-24
- Volume
- 67
- Issue
- 8
- Pages
- 1471-1480
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC6054443
- OpenAlex
- W2808896902
- Cited by
- 590
- References
- 51
- Citations by year
- 2026: 41 · 2025: 75 · 2024: 76 · 2023: 90 · 2022: 80 · 2021: 92 · 2020: 69 · 2019: 52 · 2018: 14
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK057846, UC4 DK116290)
- Leona M. and Harry B. Helmsley Charitable Trust (2018PG-T1D059)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- immune checkpoint inhibitors, type 1 diabetes, anti-PD-1, PD-L1 inhibitors, immune-related adverse events, ketoacidosis, pancreatitis, autoantibodies, HLA-DR4, solid organ cancer, endocrine adverse events
- MeSH terms
- Antineoplastic Agents, Immunological, Insulin Secretion, Animals, Autoimmune Diseases, Diabetes Mellitus, Type 1, Genotype, Humans, Hypoglycemic Agents, Insulin, Isoantibodies, Ketosis, Neoplasms, Pancreas, Pancreatitis, HLA-DR4 Antigen, Models, Immunological, Genetic Predisposition to Disease, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
